Endy's, points to another problem with combining the two approaches: fears about confidentiality. "Inevitably, when Codon partnered with, say, a company pursuing biofuels, any other biofuels company was bound to feel uneasy about shipping designs for genes or genetic circuits off to Codon. "
Codon seemed to recognize the problems in its approach. In March 2008, it received a cash infusion of $31 million from its existing investors, including such well-connected figures as Vinod Khosla of Khosla Ventures in Menlo Park and Michael Hunkapiller of Alloy Ventures in Palo Alto, California. Three months later, it said it would streamline its business and refocus on applications rather than synthesis. The move may have come too late, says Church. "A lot of our burn rate would be having a sales staff," he explains. "Codon should have stuck with its long-term plan": to provide the "foundational platform" for synthetic biology, as Intel provides a platform for computing.
Still, some analysts are perplexed that Codon's board hasn't explained why the company decided to pull the plug so suddenly. "The lack of explanation as to why Codon Devices is reported to be 'quietly shutting down' strikes me as very odd, " says Steve Aldrich, president of Bio Economic Research Associates in Cambridge, Massachusetts. "I would have thought that the controlling venture investors would be anxious to reassure public markets, which might interpret the abandonment of such a high-profile start-up as a negative judgement on the idea that we would be able to rapidly design, engineer and commercialize biological applications anytime soon. "
Drug companies are keen to use synthetic biology to improve drug development, according to Richard Kitney of Imperial College London's centre for synthetic biology, and this raises the question of why the company didn't find a larger concern to buy it up.
Khosla, Hunkapiller, Endy and Jacobson did not respond to requests to comment for this piece. But other scientists say that synthetic biology has a bright future that need not hinge on the fate of a single firm. "This is a young, exciting and dynamic field, and this is one of the companies that tried to make it and failed in a pretty tough environment, " says Sven Panke of the Swiss Federal Institute of Technology in Zurich. "It will take time; that's what you would expect. " Indeed, one of the most promising applications of synthetic biology is thought to lie in the development of better biofuels. In 2007, Church launched a separate synthetic-biology biofuels company, LS9, in South San Francisco, with backing from Khosla, among others. Khosla is also an investor in an earlier Keasling start-up, Amyris Biotechnologies of Emeryville, California, which has begun working on biofuels and is developing cheaper antimalarial drugs in partnership with the Paris-based pharmaceutical company Sanofi-Aventis and the San Francisco-based non-profit Institute for OneWorld Health.
These and other competing ventures may have made life more difficult for Codon, which was recruiting biofuels partners. "You've got the combination of many more [start-ups] 
